Jurkat细胞
转染
嵌合抗原受体
电穿孔
细胞生物学
基因传递
分子生物学
细胞培养
生物
T细胞
化学
免疫学
免疫系统
生物化学
遗传学
基因
作者
Pedro Henrique Dias Moura Prazeres,Heloísa Athaydes Seabra Ferreira,Pedro Augusto Carvalho Costa,Walison da Silva,Marco Túllio Rodrigues Alves,Marshall Scott Padilla,Ajay S. Thatte,Anderson Kenedy Santos,Anderson Oliveira Lobo,Adriano de Paula Sabino,Helen Lima Del Puerto,Michael J. Mitchell,Pedro Pires Goulart Guimarães
摘要
Introduction: Chimeric antigen receptor (CAR) cell therapy represents a hallmark in cancer immunotherapy, with significant clinical results in the treatment of hematological tumors. However, current approved methods to engineer T cells to express CAR use viral vectors, which are integrative and have been associated with severe adverse effects due to constitutive expression of CAR. In this context, non-viral vectors such as ionizable lipid nanoparticles (LNPs) arise as an alternative to engineer CAR T cells with transient expression of CAR. Methods: Here, we formulated a mini-library of LNPs to deliver pDNA to T cells by varying the molar ratios of excipient lipids in each formulation. LNPs were characterized and screened in vitro using a T cell line (Jurkat). The optimized formulation was used ex vivo to engineer T cells derived from human peripheral blood mononuclear cells (PBMCs) for the expression of an anti-CD19 CAR (CAR-CD19BBz). The effectiveness of these CAR T cells was assessed in vitro against Raji (CD19 + ) cells. Results: LNPs formulated with different molar ratios of excipient lipids efficiently delivered pDNA to Jurkat cells with low cytotoxicity compared to conventional transfection methods, such as electroporation and lipofectamine. We show that CAR-CD19BBz expression in T cells was transient after transfection with LNPs. Jurkat cells transfected with our top-performing LNPs underwent activation when exposed to CD19 + target cells. Using our top-performing LNP-9-CAR, we were able to engineer human primary T cells to express CAR-CD19BBz, which elicited significant specific killing of CD19 + target cells in vitro. Conclusion: Collectively, our results show that LNP-mediated delivery of pDNA is a suitable method to engineer human T cells to express CAR, which holds promise for improving the production methods and broader application of this therapy in the future. Keywords: lipid nanoparticles, pDNA delivery, CAR T cells, cell engineering, cancer immunotherapy
科研通智能强力驱动
Strongly Powered by AbleSci AI